基本信息
浏览量:253
职业迁徙
个人简介
Allan H. Friedman, MD, is an internationally recognized tumor and vascular neurosurgeon. He has a career-long interest in neuro-oncology, is responsible for over ninety percent of all tumor resections and biopsies conducted at Duke, and has written hundreds of articles on the neurosurgical management of brain tumors and vascular lesions. He is head of the Laboratory of Neurosurgical Oncology and an Associate Chief of the Preuss Laboratory for Brain Tumor Research.
At the present time, I am participating in collaborative research in the areas of primary malignant brain tumors, epilepsy and subarachnoid hemorrhage.
Primary malignant brain tumors are increasing in frequency. Patients harboring glioblastoma, the most malignant primary brain tumor, have a life expectancy of less than one year. In colloboration with the Division of Neurology and the Department of Pathology, clinical and laboratory trials have been initiated to identify better treatment for this condition. At present, trials of monoclonal antibodies and novel chemotherapeutic agents are being carried out.
Although physicians have been interested in seizures since the time of Hippocrates, the origin of seizures remains obscure. At Duke University we have treated approximately thirty seizure patients a year by removing abnormal portions of brain. Tissue from these resections is being analyzed for genetics and receptor abnormalities. Positron emission tomography and magnetic resonance imaging are being used to ferret out the origin of the patient's seizures.
Approximately 28,000 patients each year suffer a ruptured intracranial aneurysm. Approximately ten percent of these patients have a genetic predisposition to forming intracranial aneurysms. In conjunction with the Division of Neurology, we are screening candidate genes searching for the cause of intracranial aneurysms.
At the present time, I am participating in collaborative research in the areas of primary malignant brain tumors, epilepsy and subarachnoid hemorrhage.
Primary malignant brain tumors are increasing in frequency. Patients harboring glioblastoma, the most malignant primary brain tumor, have a life expectancy of less than one year. In colloboration with the Division of Neurology and the Department of Pathology, clinical and laboratory trials have been initiated to identify better treatment for this condition. At present, trials of monoclonal antibodies and novel chemotherapeutic agents are being carried out.
Although physicians have been interested in seizures since the time of Hippocrates, the origin of seizures remains obscure. At Duke University we have treated approximately thirty seizure patients a year by removing abnormal portions of brain. Tissue from these resections is being analyzed for genetics and receptor abnormalities. Positron emission tomography and magnetic resonance imaging are being used to ferret out the origin of the patient's seizures.
Approximately 28,000 patients each year suffer a ruptured intracranial aneurysm. Approximately ten percent of these patients have a genetic predisposition to forming intracranial aneurysms. In conjunction with the Division of Neurology, we are screening candidate genes searching for the cause of intracranial aneurysms.
研究兴趣
论文共 463 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
Annick Desjardins,Vidya Chandramohan,Daniel Landi, Katherine B. Peters,Margaret Johnson,Justin Low,Mustafa Khasraw, Stevie Threatt,Chevelle Bullock,James E. Herndon,Eric Lipp,Allan H. Friedman,
Neuro-oncologyno. Supplement_5 (2023): v62-v63
引用0浏览0引用
0
0
Kirit Singh,Kelly Hotchkiss, Matthew W. Foster, Cindy Railton, Emily Blandford, Elizabeth Thomas,Elizabeth Miller,David Ashley,Annick Desjardins,Henry S. Friedman,Margaret Johnson,Allan H. Friedman,
Neuro-oncologyno. Supplement_5 (2023): v63-v63
引用0浏览0引用
0
0
openalex(2023)
crossref(2023)
crossref(2023)
CUREUS JOURNAL OF MEDICAL SCIENCEno. 7 (2022)
medRxivno. 3 (2022)
引用2浏览0引用
2
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn